Distribuzione geografica
Continente #
NA - Nord America 3179
EU - Europa 394
AF - Africa 192
AS - Asia 115
Continente sconosciuto - Info sul continente non disponibili 20
SA - Sud America 5
OC - Oceania 3
Totale 3908
Nazione #
US - Stati Uniti d'America 3112
NG - Nigeria 191
FR - Francia 98
IT - Italia 91
CA - Canada 67
NL - Olanda 61
TR - Turchia 52
DE - Germania 40
GB - Regno Unito 37
IL - Israele 24
FI - Finlandia 21
BE - Belgio 15
EU - Europa 13
IR - Iran 12
IE - Irlanda 8
A2 - ???statistics.table.value.countryCode.A2??? 7
CN - Cina 7
IN - India 5
CH - Svizzera 4
CL - Cile 4
ID - Indonesia 4
TW - Taiwan 4
UA - Ucraina 4
AU - Australia 3
SE - Svezia 3
ES - Italia 2
GR - Grecia 2
RO - Romania 2
RU - Federazione Russa 2
AT - Austria 1
BD - Bangladesh 1
BG - Bulgaria 1
BR - Brasile 1
DK - Danimarca 1
EG - Egitto 1
HK - Hong Kong 1
IQ - Iraq 1
JP - Giappone 1
LA - Repubblica Popolare Democratica del Laos 1
NO - Norvegia 1
SG - Singapore 1
VN - Vietnam 1
Totale 3908
Città #
Wilmington 916
Chandler 486
San Mateo 379
Ann Arbor 265
Benin City 191
Lawrence 187
Princeton 187
Leawood 180
Woodbridge 121
Fairfield 102
Paris 98
Amsterdam 61
Toronto 55
Kocaeli 52
Milan 34
London 33
Boardman 31
San Diego 25
Redwood City 24
Seattle 24
Norwalk 22
Helsinki 20
Brussels 15
Monmouth Junction 13
Redmond 11
Dublin 8
Andover 7
Winnipeg 7
Ardabil 6
Des Moines 6
Abbiategrasso 5
Clearwater 5
Houston 5
Nanjing 5
Phoenix 5
Apo 4
Frankfurt am Main 4
Jakarta 4
Fiumicino 3
Rome 3
Sacramento 3
San Marcello Pistoiese 3
Taipei 3
Ashburn 2
Buffalo 2
Cambridge 2
Collegeville 2
Indianapolis 2
Jacksonville 2
Niscemi 2
Ottawa 2
Parma 2
Vancouver 2
Addison 1
Adliswil 1
Albano Laziale 1
Aprilia 1
Athens 1
Basel 1
Beijing 1
Borås 1
Cairo 1
Chennai 1
Crema 1
Dalsjoefors 1
Dhaka 1
Eden Prairie 1
Espoo 1
Giardini 1
Gunzenhausen 1
Hanoi 1
Hanover 1
Hockessin 1
Hyderabad 1
Kemerovo 1
Modesto 1
Novokuznetsk 1
Padova 1
Pittsfield 1
Pomezia 1
Potomac 1
Rockville 1
Sachsen 1
Saint Louis 1
San Francisco 1
Santiago 1
Shanghai 1
Smithtown 1
Sofia 1
Stockholm 1
Sydney 1
São Paulo 1
Wells 1
Zanjan 1
Totale 3679
Nome #
721P Ipilimumab and nivolumab compassionate use program in metastatic renal cell carcinoma patients with intermediate or poor IMDC risk score: The large multicenter Italian study 45
Response to Sunitinib in an Adult Patient With Rhabdoid Renal Cell Carcinoma 43
Phase II study of avelumab plus intermittent axitinib in previously untreated patients with metastatic renal cell carcinoma (Tide-A study) 42
Gene methylation in pleural mesothelioma : Correlations with clinico-pathological features and patient’s follow-up 39
Targeted therapy for thymic epithelial tumors: a new horizon ? Review of the literature and two cases reports 39
Activity of a specific inhibitor, gefitinib (Iressa, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer 39
Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy 39
Association of Polymorphisms in AKT1 and EGFR with Clinical Outcome and Toxicity in Non-Small Cell Lung Cancer Patients Treated with Gefitinib 36
Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer 36
Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1 in patients with hepatocellular carcinoma 36
New tricks for old biomarkers: thymidylate synthase expression as a predictor of pemetrexed activity in malignant mesothelioma 35
Prophylaxis of central venous catheter-related thrombosis with minidose warfarin: Analysis of its use in 427 cancer patients 34
Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors 34
Minidose warfarin prophylaxis for catheter-associated thrombosis in cancer patients: Can it be safely associated with fluorouracil-based chemotherapy? 34
Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors 34
Management of germ cell tumors during the outbreak of the novel coronavirus disease‐19 pandemic: a survey of international expertise centers 34
Baseline Radiomic CT Features Differentiate Mediastinal Masses As Thymic Neoplasms Or Lymphomas 33
Checkpoint inhibitors as treatment for malignant gliomas: "A long way to the top" 33
A phase II study of the combination of gemcitabine and imatinib mesylate in pemetrexed-pretreated patients with malignant pleural mesothelioma 33
Expression and mutational status of c-kit in thymic epithelial tumors 32
Carbon-11-methionine PET-CT as an imaging biomarker in brain gliomas eligible for surgery 32
Reproducibility of the WHO classification of thymomas: practical implications 32
Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [F-18]fluorodeoxyglucose 31
Minidose warfarin is associated with a high incidence of International Normalized Ratio elevation during chemotherapy with FOLFOX regimen 31
Computed tomography (CT)-derived radiomic features differentiate prevascular mediastinum masses as thymic neoplasms versus lymphomas 31
Short schedule of cisplatin and vinorelbine: A dose-finding study in non-small-cell lung cancer 30
Baseline and early change of systemic inflammation index (bSII and ΔSII) as prognostic factors in metastatic renal cell carcinoma (mRCC) patients treated with Nivolumab: Final results of the Meet-URO 15 (I-BIO-REC) study 30
Irinotecan and raltitrexed: an active combination in advanced colorectal cancer 29
Prognostic value of molecular and imaging biomarkers in patients with supratentorial glioma 29
Prognostic and predictive role of [F-18]fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up-front pemetrexed-based chemotherapy 29
Changes in shedding of soluble tumor necrosis factor receptors (sR1/R2) and in dynamic MRI as early predictors of outcome with NGR-hTNF 29
The neural phenotype in invasive urothelial carcinoma patients: Alternative score detection and prognostic implication 29
Available evidence and new biological perspectives on medical treatment of advanced thymic epithelial tumors 29
Bladder metastases of appendiceal mucinous adenocarcinoma: a case presentation 29
2-¹⁸fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial 29
Second-line chemotherapy in malignant pleural mesothelioma: Results of a retrospective multicenter survey 28
Addition of temozolomide to radiotherapy for treatment of newly diagnosed anaplastic gliomas 28
Survival Outcomes in Malignant Pleural Mesothelioma Patients Fit for Surgery According to Type of Procedure and Completeness of Resection 28
Comorbidity, postoperative morbidity and survival in patients undergoing radical surgery for malignant pleural mesothelioma 28
Imaging biomarkers in primary brain tumours 28
Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors 28
MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients 27
Assessment of tumor response in malignant pleural mesothelioma 27
Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma 27
Thymidylate Synthase and Excision Repair Cross-Complementing Group-1 as Predictors of Responsiveness in Mesothelioma Patients Treated with Pemetrexed/Carboplatin 27
Randomized phase II study on gemcitabine with or without ramucirumab as second-line treatment for advanced malignant pleural mesothelioma (MPM): Results of Italian Rames Study 27
Safety and activity of Combined AVElumab with Axitinib in unresectable or metastatic Thymomas B3 and Thymic carcinomas: The CAVEATT study 27
The Role of Pemetrexed in the Pharmacotherapy of Malignant Pleural Mesothelioma 26
Retrospective analysis of an alternative immuno-score in clinical management of patients with pT2 urothelial carcinoma 26
Malignant Pleural Mesothelioma: Extrapleural Pneumonectomy and medical treatment in 60 patients 25
Positron emission tomography with F18-fluorodeoxyglucose (FDG-PET) in malignant pleural mesothelioma (MPM): Prediction of response to chemotheraphy by quantitative assessment of standard uptake value (SUV) 25
Phase II study of Pemetrexed and Carboplatin plus Bevacizumab as first-line therapy in malignant pleural mesothelioma 25
Malignant pleural mesothelioma (MPM) evaluation with C-11-methionine PET/CT before and after talc pleurodesis 25
Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin 25
Advances in the biology of malignant pleural mesothelioma 25
Pharmacodynamic (PD) evaluation of soluble proteins from a phase I trial of lapatinib (L) in combination with sorafenib (S) 25
Vinorelbine as second or third-line therapy in pemetrexed-pretreated malignant pleural mesothelioma (MPM) patients 25
Antiproliferative effects of novel aliphatic acetogenin analogs against aggressive solid tumor cell lines 25
Biology and management of malignant pleural mesothelioma 25
Anti-angiogenic therapies for malignant pleural mesothelioma 25
Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma 25
Morphometric vertebral fractures in patients with castration-resistant prostate cancer undergoing treatment with radium-223: a longitudinal study in the real-life clinical practice. 24
Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma 24
Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME) 24
Future developments in the management of malignant pleural mesothelioma 24
Insulin-Like Growth Factor-1 Receptor and Phosphorylated AKT-Serine 473 Expression in 132 Resected Thymomas and Thymic Carcinomas 24
On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2 24
Can sentinel node biopsy avoid axillary dissection in clinically node-negative breast cancer patients? 24
Baseline and early change of neutrophil to lymphocyte ratio (bNLR and ΔNLR) as prognostic factors in metastatic renal cell carcinoma (mRCC) treated with Nivolumab: Final results of the Meet-URO 15 (I-BIO-REC) study 24
NGR-hTNF, a vascular targeting agent (VTA), in previously treated patients with malignant pleural mesothelioma (MPM): a phase II study 23
Phase I study of PF-03446962 (anti-ALK-1 mAb) in hepatocellular carcinoma (HCC) 23
Phase I study of NGR-hTNF administered at high doses in refractory patients with solid tumors 23
Phase I, pharmacokinetics, pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors 23
Role of SBRT with VMAT technique and FFF beams for lymph-node metastases in oligometastatic patients from genitourinary malignancies 23
Malignant pleural mesothelioma 23
Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01–2014) 23
Positron emission tomography with F18-fluorodeoxyglucose (FDG-PET) in malignant pleural mesothelioma (MPM): Evaluation of response to chemotherapy by quantitative assessment of standardized uptake value (SUV) 22
The "old drug" dacarbazine as a second/third line chemotherapy in advanced soft tissue sarcomas 22
Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with solid tumors 22
Parametrical analyses at baseline and interim PET for response assessment and outcome definition in patients affected by malignant pleural mesothelioma (MPM) 22
Phase I, pharmacokinetic (PK), pharmacodynamic (PD) study of lapatinib (L) in combination with sorafenib (S) in patients with advanced refractory solid tumors 22
Phase I, Pharmacokinetics (PK), Pharmacodynamic (PD) Study of Lapatinib (L) in Combination With Sorafenib (S) in Patients With Advanced Refractory Solid Tumours 22
Src as a potential therapeutic target in non-small-cell lung cancer 22
SAKK 17/16 - Lurbinectedin as second or third line palliative chemotherapy in malignant pleural mesothelioma (MPM): A multi-center, single-arm phase II trial 22
Role of chemotherapy in combination with hormonal therapy in first-line treatment of metastatic hormone-sensitive prostate cancer 22
SNPs in PI3K-PTEN-mTOR and brain metastases in NSCLC--letter 22
EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations 21
A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis 21
Uncommon manifestations of common malignancies - Case 1. Soft-tissue metastases from malignant pleural mesothelioma 21
Timing of response evaluation with 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) in malignant pleural mesothelioma (MPM): "Early'' versus "late'' assessment 21
Phase I safety, pharmacokinetic (PK), and pharmacodynamic (PD) trial of NGR-hTNF given at high doses in patients with refractory solid tumors 21
Tivantinib in combination with Carboplatin and Pemetrexed as first line treatment in patients with advanced non-squamous NSCLC or Malignant Pleural Mesothelioma: results of phase I trial 21
Final results from ARQ 197-114: A phase 1b safety trial evaluating ARQ 197 in cirrhotic patients (pts) with hepatocellular carcinoma (HCC) 21
"One marker does not fit all": additional translational and validation studies are needed to identify faithful predictors of pemetrexed activity in mesothelioma 21
Optimizing Anti-EGFR Strategies in Cancer Treatment 21
Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study 21
Totale 2737
Categoria #
all - tutte 23067
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23067

Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202040 0000 00 00 00040
2020/20211940 18162315 13663 287120 3602167202
2021/20221017 492928186 156 37128 10111229135
2022/20231116 40663215168 131125 80 0000
Totale 4113